SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001689813-22-000075
Filing Date
2022-09-19
Accepted
2022-09-19 17:20:25
Documents
14
Period of Report
2022-09-19
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K bhvn-20220919.htm   iXBRL 8-K 30639
2 EX-5.1 september2022maplesopinion.htm EX-5.1 34204
6 image_0.jpg GRAPHIC 83636
  Complete submission text file 0001689813-22-000075.txt   305851

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bhvn-20220919.xsd EX-101.SCH 1926
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bhvn-20220919_lab.xml EX-101.LAB 23892
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bhvn-20220919_pre.xml EX-101.PRE 12600
8 EXTRACTED XBRL INSTANCE DOCUMENT bhvn-20220919_htm.xml XML 10541
Mailing Address 215 CHURCH STREET NEW HAVEN CT 06510
Business Address 215 CHURCH STREET NEW HAVEN CT 06510 203-404-0410
Biohaven Pharmaceutical Holding Co Ltd. (Filer) CIK: 0001689813 (see all company filings)

IRS No.: 000000000 | State of Incorp.: D8 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38080 | Film No.: 221251367
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences